Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Urotainer Suby G is a sterile, non-pyrogenic catheter maintenance solution developed by B. Braun, designed to prevent and dissolve mineral encrustations on indwelling urinary catheters. The solution is formulated with citric acid, which acts as an acidifying agent to dissolve calcium and magnesium phosphate deposits (such as hydroxyapatite and struvite) that can lead to catheter blockage and provide a niche for bacterial biofilm. To ensure patient safety and comfort, the formulation includes magnesium oxide as a buffering agent, which raises the pH slightly to reduce irritation of the bladder mucosa compared to pure citric acid solutions. It is typically administered via a closed-system irrigation bag to maintain sterility and reduce the risk of catheter-associated urinary tract infections (CAUTIs).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Uro-Tainer Suby G.